Trial Outcomes & Findings for TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy (NCT NCT02186301)

Last Updated: 2019-05-07

Results Overview

To compare the antitumor efficacy of oral single-agent rociletinib with that of erlotinib as measured by progression-free survival (PFS), when administered as a first-line targeted treatment to patients with EGFR-mutated, advanced NSCLC.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.The appearance of one or more new lesions is also considered progression.

Recruitment status

TERMINATED

Study phase

PHASE2/PHASE3

Target enrollment

100 participants

Primary outcome timeframe

Cycle 1 Day 1 to End of Treatment, up to approximately 35 months

Results posted on

2019-05-07

Participant Flow

100 subjects recruited from 74 sites, in 7 countries and randomized (1:1) to treatment with rociletinib or erlotinib.Original protocol had rociletinib starting dose of 625mg. In global Amendment 2, starting dose reduced to 500mg. Crossover to rociletinib was permitted however, only 2 patients did so. Safety data for these 2 patients are reported.

Participant milestones

Participant milestones
Measure	Rociletinib 500mg Tablets Starting dose of 500mg. Taken orally twice daily (continuous 28 day treatment cycle). Treatment duration until radiographically confirmed disease progression.	Rociletinib 625mg Tablets Starting dose of 625mg. Taken orally twice daily (continuous 28 day treatment cycle). Treatment duration until radiographically confirmed disease progression.	Erlotinib 150mg Tablets Starting dose of 150mg. Taken orally once daily (continuous 28 day treatment cycle). Treatment duration until radiographically confirmed disease progression.
Overall Study STARTED	20	30	50
Overall Study COMPLETED	0	0	0
Overall Study NOT COMPLETED	20	30	50

Reasons for withdrawal

Reasons for withdrawal
Measure	Rociletinib 500mg Tablets Starting dose of 500mg. Taken orally twice daily (continuous 28 day treatment cycle). Treatment duration until radiographically confirmed disease progression.	Rociletinib 625mg Tablets Starting dose of 625mg. Taken orally twice daily (continuous 28 day treatment cycle). Treatment duration until radiographically confirmed disease progression.	Erlotinib 150mg Tablets Starting dose of 150mg. Taken orally once daily (continuous 28 day treatment cycle). Treatment duration until radiographically confirmed disease progression.
Overall Study Progressive Disease	7	22	27
Overall Study Adverse Event	5	5	5
Overall Study Death	1	0	0
Overall Study Withdrawal by Subject	5	1	3
Overall Study Physician Decision	1	0	1
Overall Study Study Terminated by Sponsor	1	0	11
Overall Study Protocol Deviation	0	2	0
Overall Study Missing	0	0	2
Overall Study Other	0	0	1

Baseline Characteristics

TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Rociletinib 500mg Tablets n=20 Participants Starting dose of 500mg. Taken orally twice daily (continuous 28 day treatment cycle). Treatment duration until radiographically confirmed disease progression.	Rociletinib 625mg Tablets n=30 Participants Starting dose of 625mg. Taken orally twice daily (continuous 28 day treatment cycle). Treatment duration until radiographically confirmed disease progression.	Erlotinib 150mg Tablets n=50 Participants Starting dose of 150mg. Taken orally once daily (continuous 28 day treatment cycle). Treatment duration until radiographically confirmed disease progression.	Total n=100 Participants Total of all reporting groups
Age, Customized	66.0 years n=99 Participants	67.0 years n=107 Participants	64 years n=206 Participants	65 years n=7 Participants
Sex: Female, Male Female	17 Participants n=99 Participants	18 Participants n=107 Participants	32 Participants n=206 Participants	67 Participants n=7 Participants
Sex: Female, Male Male	3 Participants n=99 Participants	12 Participants n=107 Participants	18 Participants n=206 Participants	33 Participants n=7 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=99 Participants	3 Participants n=107 Participants	6 Participants n=206 Participants	9 Participants n=7 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	19 Participants n=99 Participants	27 Participants n=107 Participants	43 Participants n=206 Participants	89 Participants n=7 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	1 Participants n=99 Participants	0 Participants n=107 Participants	1 Participants n=206 Participants	2 Participants n=7 Participants
Race/Ethnicity, Customized American Indian or Alaska Native	0 Participants n=99 Participants	0 Participants n=107 Participants	0 Participants n=206 Participants	0 Participants n=7 Participants
Race/Ethnicity, Customized Asian	9 Participants n=99 Participants	15 Participants n=107 Participants	25 Participants n=206 Participants	49 Participants n=7 Participants
Race/Ethnicity, Customized Black or African American	2 Participants n=99 Participants	2 Participants n=107 Participants	1 Participants n=206 Participants	5 Participants n=7 Participants
Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander	0 Participants n=99 Participants	0 Participants n=107 Participants	0 Participants n=206 Participants	0 Participants n=7 Participants
Race/Ethnicity, Customized White	9 Participants n=99 Participants	12 Participants n=107 Participants	21 Participants n=206 Participants	42 Participants n=7 Participants
Race/Ethnicity, Customized Other	0 Participants n=99 Participants	0 Participants n=107 Participants	1 Participants n=206 Participants	1 Participants n=7 Participants
Race/Ethnicity, Customized Missing	0 Participants n=99 Participants	1 Participants n=107 Participants	2 Participants n=206 Participants	3 Participants n=7 Participants
Race/Ethnicity, Customized Non-White, Non-Asian	2 Participants n=99 Participants	3 Participants n=107 Participants	4 Participants n=206 Participants	9 Participants n=7 Participants
Number of Previous Therapies	0.0 units on a scale n=99 Participants	0.0 units on a scale n=107 Participants	0.0 units on a scale n=206 Participants	0.0 units on a scale n=7 Participants
Time Since Diagnosis of NSCLC	7.2 months STANDARD_DEVIATION 14.12 • n=99 Participants	5.3 months STANDARD_DEVIATION 10.39 • n=107 Participants	8.2 months STANDARD_DEVIATION 21.83 • n=206 Participants	7.1 months STANDARD_DEVIATION 17.57 • n=7 Participants
History of CNS Metastases	1 Participants n=99 Participants	1 Participants n=107 Participants	2 Participants n=206 Participants	4 Participants n=7 Participants

PRIMARY outcome

Timeframe: Cycle 1 Day 1 to End of Treatment, up to approximately 35 months

Population: Intent-to-treat: All patients randomized. 1 patient was not included in analysis, due to discontinuation of study shortly after randomization and prior to first dose of study drug.

Outcome measures

Outcome measures
Measure	Rociletinib 500mg Tablets n=18 Participants Starting dose of 500mg. Taken orally twice daily (continuous 28 day treatment cycle). Treatment duration until radiographically confirmed disease progression.	Rociletinib 625mg Tablets n=30 Participants Starting dose of 625mg. Taken orally twice daily (continuous 28 day treatment cycle). Treatment duration until radiographically confirmed disease progression.	Erlotinib 150mg Tablets n=50 Participants Starting dose of 150mg. Taken orally once daily (continuous 28 day treatment cycle). Treatment duration until radiographically confirmed disease progression.
Progression Free Survival (PFS) According to RECIST Version 1.1 as Determined by Investigator Review (invPFS)	274 Days Interval 109.0 to Upper Confidence Limit is not available because it cannot be calculated.	207 Days Interval 112.0 to 260.0	390 Days Interval 282.0 to 499.0

SECONDARY outcome

Timeframe: Cycle 1 Day 1 to End of Treatment, up to approximately 35 months.

Population: Intent-to-treat: All patients randomized

Proportion of patients with a best overall confirmed response of partial response (PR) or complete response (CR) recorded from the start of the treatment until disease progression or recurrence. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions, defined by and assessed as: Complete Response (CR), is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR),at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter. Overall Response (OR),is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). The patient's best response assignment was dependent on the achievement of both measurement and confirmation criteria.

Outcome measures

Outcome measures
Measure	Rociletinib 500mg Tablets n=20 Participants Starting dose of 500mg. Taken orally twice daily (continuous 28 day treatment cycle). Treatment duration until radiographically confirmed disease progression.	Rociletinib 625mg Tablets n=30 Participants Starting dose of 625mg. Taken orally twice daily (continuous 28 day treatment cycle). Treatment duration until radiographically confirmed disease progression.	Erlotinib 150mg Tablets n=50 Participants Starting dose of 150mg. Taken orally once daily (continuous 28 day treatment cycle). Treatment duration until radiographically confirmed disease progression.
Confirmed Response Rate	25.0 percentage of participants Interval 8.7 to 49.1	40.0 percentage of participants Interval 22.7 to 59.4	78.0 percentage of participants Interval 64.0 to 88.5

SECONDARY outcome

Timeframe: Cycle 1 Day 1 to End of Treatment, up to approximately 35 months

Duration of Response in Patients with Confirmed Response per Investigator

Outcome measures

Outcome measures
Measure	Rociletinib 500mg Tablets n=5 Participants Starting dose of 500mg. Taken orally twice daily (continuous 28 day treatment cycle). Treatment duration until radiographically confirmed disease progression.	Rociletinib 625mg Tablets n=12 Participants Starting dose of 625mg. Taken orally twice daily (continuous 28 day treatment cycle). Treatment duration until radiographically confirmed disease progression.	Erlotinib 150mg Tablets n=39 Participants Starting dose of 150mg. Taken orally once daily (continuous 28 day treatment cycle). Treatment duration until radiographically confirmed disease progression.
Duration of Response	225 Days Interval 113.0 to Upper Confidence Limit is not available because it cannot be calculated.	195.5 Days Interval 143.0 to 617.0	335.0 Days Interval 282.0 to 480.0

Adverse Events

Rociletinib 500mg Tablets

Serious events: 10 serious events

Other events: 19 other events

Deaths: 3 deaths

Rociletinib 625mg Tablets

Serious events: 15 serious events

Other events: 30 other events

Deaths: 1 deaths

Erlotinib 150mg Tablets

Serious events: 7 serious events

Other events: 50 other events

Deaths: 2 deaths

Crossover From Erlotinib 150mg to Rociletinib 500mg

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Crossover From Erlotinib 150mg to Rociletinib 625mg

Serious events: 1 serious events

Other events: 1 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Rociletinib 500mg Tablets n=19 participants at risk Starting dose of 500mg. Taken orally twice daily (continuous 28 day treatment cycle). Treatment duration until radiographically confirmed disease progression.	Rociletinib 625mg Tablets n=30 participants at risk Starting dose of 625mg. Taken orally twice daily (continuous 28 day treatment cycle). Treatment duration until radiographically confirmed disease progression.	Erlotinib 150mg Tablets n=50 participants at risk Starting dose of 150mg. Taken orally once daily (continuous 28 day treatment cycle). Treatment duration until radiographically confirmed disease progression.	Crossover From Erlotinib 150mg to Rociletinib 500mg n=1 participants at risk Patients initially randomized to erlotinib were eligible to participate in an optional crossover phase to receive CO-1686. Starting dose of 500mg CO-1686. Taken orally twice daily (continuous 28 day treatment cycle). Treatment duration until radiographically confirmed disease progression.	Crossover From Erlotinib 150mg to Rociletinib 625mg n=1 participants at risk Patients initially randomized to erlotinib were eligible to participate in an optional crossover phase to receive CO-1686. Starting dose of 625mg. Taken orally twice daily (continuous 28 day treatment cycle). Treatment duration until radiographically confirmed disease progression.
Endocrine disorders Diabetic ketoacidosis	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Endocrine disorders Hyperglycaemia	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Respiratory, thoracic and mediastinal disorders Interstitial lung disease	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Cardiac disorders Torsade de pointes	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Skin and subcutaneous tissue disorders Dermatitis acneiform	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	2.0% 1/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Hepatobiliary disorders Acute cholangtis, Acute cholecystitis and acute	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Blood and lymphatic system disorders Anaemia	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Cardiac disorders Angina pectoris	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Cardiac disorders Pericardial effusion	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Cardiac disorders Tachycardia	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	2.0% 1/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Eye disorders Cataract	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Gastrointestinal disorders Abdominal pain upper	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Gastrointestinal disorders Nausea	10.5% 2/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Gastrointestinal disorders Pancreatitis	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Gastrointestinal disorders Vomiting	10.5% 2/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
General disorders Catheter site haematoma	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
General disorders Fatigue	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	2.0% 1/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
General disorders Non-cardiac chest pain	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Hepatobiliary disorders Cholecystitis	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Hepatobiliary disorders Cholecystitis acute	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Infections and infestations Enterocolitis infectious	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	2.0% 1/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Infections and infestations Pneumonia	10.5% 2/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.7% 2/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	4.0% 2/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Infections and infestations Pneumonia viral	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Infections and infestations Urinary tract infection	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	2.0% 1/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Injury, poisoning and procedural complications Femur fracture	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Injury, poisoning and procedural complications Radius fracture	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Injury, poisoning and procedural complications Subdural haematoma	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Investigations Cardiac murmur	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	2.0% 1/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Metabolism and nutrition disorders Dehydration	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	2.0% 1/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Metabolism and nutrition disorders Diabetic ketoacidosis	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Metabolism and nutrition disorders Hyperglycaemia	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Metabolism and nutrition disorders Polydipsia	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	2.0% 1/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant neoplasm progression	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	2.0% 1/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	100.0% 1/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to bone	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Nervous system disorders Cerebrovascular accident	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	2.0% 1/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Nervous system disorders Syncope	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Renal and urinary disorders Renal failure acute	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Respiratory, thoracic and mediastinal disorders Acute respiratory failure	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Respiratory, thoracic and mediastinal disorders Paranasal cyst	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	2.0% 1/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Respiratory, thoracic and mediastinal disorders Pleural effusion	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Respiratory, thoracic and mediastinal disorders Pneumonia aspiration	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	2.0% 1/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Investigations Ejection fraction decreased	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	100.0% 1/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.

Other adverse events

Other adverse events
Measure	Rociletinib 500mg Tablets n=19 participants at risk Starting dose of 500mg. Taken orally twice daily (continuous 28 day treatment cycle). Treatment duration until radiographically confirmed disease progression.	Rociletinib 625mg Tablets n=30 participants at risk Starting dose of 625mg. Taken orally twice daily (continuous 28 day treatment cycle). Treatment duration until radiographically confirmed disease progression.	Erlotinib 150mg Tablets n=50 participants at risk Starting dose of 150mg. Taken orally once daily (continuous 28 day treatment cycle). Treatment duration until radiographically confirmed disease progression.	Crossover From Erlotinib 150mg to Rociletinib 500mg n=1 participants at risk Patients initially randomized to erlotinib were eligible to participate in an optional crossover phase to receive CO-1686. Starting dose of 500mg CO-1686. Taken orally twice daily (continuous 28 day treatment cycle). Treatment duration until radiographically confirmed disease progression.	Crossover From Erlotinib 150mg to Rociletinib 625mg n=1 participants at risk Patients initially randomized to erlotinib were eligible to participate in an optional crossover phase to receive CO-1686. Starting dose of 625mg. Taken orally twice daily (continuous 28 day treatment cycle). Treatment duration until radiographically confirmed disease progression.
Infections and infestations Paronychia	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	20.0% 10/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Endocrine disorders Combined Terms of Hyperglycemia	52.6% 10/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	53.3% 16/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.0% 3/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Cardiac disorders Combined Terms of QTc Prolongation	10.5% 2/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	26.7% 8/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	2.0% 1/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Skin and subcutaneous tissue disorders Combined Terms of Rash	26.3% 5/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	13.3% 4/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	86.0% 43/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Blood and lymphatic system disorders Anaemia	31.6% 6/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.7% 2/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	2.0% 1/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	100.0% 1/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Blood and lymphatic system disorders Leukopenia	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.7% 2/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Blood and lymphatic system disorders Thrombocytopenia	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Cardiac disorders Palpitations	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.0% 3/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Cardiac disorders Tachycardia	15.8% 3/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	4.0% 2/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Ear and labyrinth disorders Ear congestion	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Eye disorders Cataract	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.7% 2/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	2.0% 1/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Eye disorders Dry eye	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	14.0% 7/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Gastrointestinal disorders Abdominal pain	15.8% 3/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	10.0% 3/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	8.0% 4/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Gastrointestinal disorders Abdominal pain upper	15.8% 3/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	4.0% 2/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Gastrointestinal disorders Constipation	15.8% 3/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	20.0% 6/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	4.0% 2/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	100.0% 1/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Gastrointestinal disorders Diarrhoea	36.8% 7/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	50.0% 15/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	66.0% 33/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Gastrointestinal disorders Dry mouth	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.0% 3/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Gastrointestinal disorders Dyspepsia	21.1% 4/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.0% 3/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Gastrointestinal disorders Gastrooesophageal reflux disease	10.5% 2/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	10.0% 3/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	12.0% 6/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	100.0% 1/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Gastrointestinal disorders Haemorrhoids	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Gastrointestinal disorders Nausea	52.6% 10/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	26.7% 8/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	14.0% 7/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	100.0% 1/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Gastrointestinal disorders Stomatitis	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.7% 2/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	18.0% 9/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Gastrointestinal disorders Vomiting	26.3% 5/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	20.0% 6/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	8.0% 4/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	100.0% 1/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
General disorders Asthenia	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.7% 2/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	4.0% 2/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
General disorders Catheter site haematoma	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
General disorders Catheter site inflammation	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
General disorders Catheter site pain	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
General disorders Chest discomfort	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.7% 2/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	4.0% 2/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
General disorders Chest pain	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.7% 2/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	8.0% 4/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
General disorders Chills	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.7% 2/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	4.0% 2/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
General disorders Fatigue	31.6% 6/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	30.0% 9/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	24.0% 12/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	100.0% 1/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
General disorders Malaise	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	10.0% 3/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
General disorders Mucosal inflammation	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
General disorders Non-cardiac chest pain	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	10.0% 5/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
General disorders Oedema peripheral	10.5% 2/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	13.3% 4/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	10.0% 5/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	100.0% 1/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
General disorders Pain	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.0% 3/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
General disorders Pyrexia	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	10.0% 3/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	4.0% 2/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Hepatobiliary disorders Cholecystitis acute	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Hepatobiliary disorders Cholecystitis chronic	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Hepatobiliary disorders Cholelithiasis	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Hepatobiliary disorders Hyperbilirubinaemia	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	2.0% 1/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Infections and infestations Bronchitis	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Infections and infestations Candida infection	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Infections and infestations Conjunctivitis	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.0% 3/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Infections and infestations Infection	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Infections and infestations Nasopharyngitis	10.5% 2/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.0% 3/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Infections and infestations Oral candidiasis	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	10.0% 3/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Infections and infestations Oral herpes	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Infections and infestations Pneumonia	10.5% 2/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	10.0% 3/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	4.0% 2/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Infections and infestations Upper respiratory tract infection	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	16.0% 8/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Infections and infestations Urinary tract infection	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	13.3% 4/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	12.0% 6/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Infections and infestations Vaginal infection	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Investigations Alanine aminotransferase increased	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	8.0% 4/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Investigations Aspartate aminotransferase increased	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	10.0% 5/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Investigations Blood alkaline phosphatase increased	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	2.0% 1/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Investigations Blood bilirubin increased	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	10.0% 5/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Investigations Blood cholesterol increased	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Investigations Blood creatinine increased	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.7% 2/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Investigations Blood lactate dehydrogenase increased	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Investigations Electrocardiogram QT prolonged	10.5% 2/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	23.3% 7/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	2.0% 1/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Investigations Neutrophil count decreased	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	100.0% 1/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Investigations Platelet count decreased	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.7% 2/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Investigations Weight decreased	15.8% 3/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	16.7% 5/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	8.0% 4/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Investigations White blood cell count decreased	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.7% 2/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Metabolism and nutrition disorders Decreased appetite	26.3% 5/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	16.7% 5/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	18.0% 9/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	100.0% 1/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Metabolism and nutrition disorders Dehydration	15.8% 3/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	10.0% 3/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	2.0% 1/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Metabolism and nutrition disorders Diabetic ketoacidosis	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Metabolism and nutrition disorders Hyperglycaemia	52.6% 10/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	50.0% 15/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	4.0% 2/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Metabolism and nutrition disorders Hyperkalaemia	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	2.0% 1/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Metabolism and nutrition disorders Hypocalcaemia	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Metabolism and nutrition disorders Hypokalaemia	15.8% 3/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.7% 2/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Metabolism and nutrition disorders Hypomagnesaemia	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	4.0% 2/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Metabolism and nutrition disorders Hyponatraemia	10.5% 2/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Metabolism and nutrition disorders Polydipsia	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.7% 2/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Musculoskeletal and connective tissue disorders Arthralgia	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.7% 2/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	8.0% 4/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	13.3% 4/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	14.0% 7/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Musculoskeletal and connective tissue disorders Muscle spasms	26.3% 5/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	16.7% 5/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.0% 3/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.7% 2/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.0% 3/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	10.5% 2/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	10.0% 5/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Musculoskeletal and connective tissue disorders Myalgia	10.5% 2/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	2.0% 1/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	12.0% 6/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant neoplasm progression	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	2.0% 1/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	100.0% 1/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Gastrointestinal disorders Abdominal discomfort	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.7% 2/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Nervous system disorders Carpal tunnel syndrome	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Nervous system disorders Dizziness	15.8% 3/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.7% 2/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	18.0% 9/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Nervous system disorders Headache	10.5% 2/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	16.7% 5/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.0% 3/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Nervous system disorders Neuropathy peripheral	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	100.0% 1/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Nervous system disorders Syncope	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	10.0% 3/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	4.0% 2/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Psychiatric disorders Anxiety	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	13.3% 4/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	14.0% 7/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Psychiatric disorders Depression	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	20.0% 6/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	8.0% 4/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Psychiatric disorders Insomnia	26.3% 5/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	10.0% 3/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	14.0% 7/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Renal and urinary disorders Renal failure acute	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	2.0% 1/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Respiratory, thoracic and mediastinal disorders Acute respiratory failure	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Respiratory, thoracic and mediastinal disorders Cough	26.3% 5/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	20.0% 6/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	26.0% 13/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	100.0% 1/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Respiratory, thoracic and mediastinal disorders Dysphonia	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.0% 3/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Respiratory, thoracic and mediastinal disorders Dyspnoea	21.1% 4/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	23.3% 7/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	14.0% 7/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	100.0% 1/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Respiratory, thoracic and mediastinal disorders Dyspnoea exertional	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.7% 2/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	4.0% 2/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.7% 2/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.7% 2/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	8.0% 4/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Respiratory, thoracic and mediastinal disorders Pleural effusion	10.5% 2/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	2.0% 1/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Respiratory, thoracic and mediastinal disorders Pneumonia aspiration	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	10.5% 2/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	12.0% 6/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	100.0% 1/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Respiratory, thoracic and mediastinal disorders Upper-airway cough syndrome	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.0% 3/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Respiratory, thoracic and mediastinal disorders Wheezing	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	2.0% 1/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Skin and subcutaneous tissue disorders Alopecia	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	16.0% 8/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Skin and subcutaneous tissue disorders Dermatitis acneiform	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	36.0% 18/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	18.0% 9/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Skin and subcutaneous tissue disorders Hyperhidrosis	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	6.7% 2/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	12.0% 6/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Skin and subcutaneous tissue disorders Pruritus generalised	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Skin and subcutaneous tissue disorders Rash	21.1% 4/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	10.0% 3/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	52.0% 26/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Skin and subcutaneous tissue disorders Rash maculo-papular	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	2.0% 1/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Skin and subcutaneous tissue disorders Skin fissures	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	8.0% 4/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Cardiac disorders Sinus tachycardia	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Eye disorders Vision blurred	5.3% 1/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	3.3% 1/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Blood and lymphatic system disorders Lymphopenia	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	100.0% 1/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Nervous system disorders Dysgeusia	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	100.0% 1/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Investigations Ejection fraction decreased	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	100.0% 1/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.
Gastrointestinal disorders Odynophagia	0.00% 0/19 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/30 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/50 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	0.00% 0/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.	100.0% 1/1 • Adverse events (AEs) were reported from the time the first dose of study drug is administered, and until 28 days after the last dose. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up. If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class). Treatment Arm/Groups for subjects (n=2) who crossed over to Rociletinib from Erlotinib are included.

Additional Information

Vi Nguyen

Clovis Oncology

Phone: +1 415 915 9982

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee All parties agree to submit all manuscripts or abstracts to all other parties 30 days prior to submission. This will enable all parties to protect proprietary information and to provide comments based on information that may not yet be available to other parties. The sponsor may request a delay in publication if there are important intellectual property concerns relating to publication, but does not have the right to suppress publication of the study results indefinitely.
Publication restrictions are in place

Restriction type: OTHER